Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
Rajesh PahwaAristide MerolaMichael SoileauAli AlobaidiA Simon PickardPrasanna L KandukuriYanjun BaoJohn StrezewskiJulia OddsdottirWeiwei XuDavid G StandaertPublished in: Movement disorders : official journal of the Movement Disorder Society (2023)
CLES is a cost-effective treatment for aPD patients with medication resistant motor fluctuations. © 2023 AbbVie, Inc and The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.